The question is when to buy and what to risk.
Oxford University, along with Britain's AstraZeneca, published promising data from an early stage trial of a key coronavirus vaccine study Monday in London.
BHVN has made a relatively big advance since April and a period of consolidation or sideways price action is probably likely at this time.
One would need to use covered calls to initiate positions that provide a solid amount of downside protection.
Let's review the charts and indicators.
I plan to add some additional exposure to each on the next 'hiccup' in the market using my usual covered call strategy.
The firm is obviously fast becoming a real player in creating treatment for certain cancers. The firm still loses money.
Japanese company Shionogi developed a noninvasive saliva test for Covid-19 that delivers results in 25 minutes, and could be used on travelers.
Potential for a new blockbuster breast cancer treatment is eyed as possible game changer, so let's see the charts and indicators for a new target.
That's the really good news about why we could bounce back so quickly from Thursday's debacle.